Contract Research Organizations Services Market By Type (Discovery, CMC, Preclinical, Clinical Research, and Laboratory Services), By Therapeutic Area (Oncology, CNS, and Cardiovascular), By End User (Pharmaceuticals & Biotechnological Companies and Medical Device Companies) and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI343219 | Publish Date: May 2024 | No. of Pages: 170

Global Contract Research Organizations Market Companies

  • Medpace, Inc.
  • Clintec
  • PRA Health Sciences, Inc.
  • ICON plc
  • KCR S.A.
  • PSI
  • Parexel International Corporation.
  • Covance Inc. 

Recent News:

  • The top biotechnology contract research organization (CRO) in Asia-Pacific, Novotech, acquired the European Contract Research Organization (EastHORN) in January 2023. EastHORN was well-known for its clinical, medical, and regulatory expertise in several strategically significant locations throughout Europe. The purchase is a component of Novotech's continuous plan to expand internationally. Customers throughout Europe, the US, and the Asia-Pacific area will now have access to Novotech's various top-notch early to late-stage Contract Research Organizations services.
  • With an estimated 21 billion dollars in value, Thermo Fisher purchased PPD in May 2023, making it the largest merger and acquisition deal involving contract research businesses of 2023. Larger-scale trials including a patient population with greater global diversity will benefit from this. The trial's operations will be improved to better follow national and international health regulations.
  • In October 2023, Saphetor SA and ICON collaborated to effectively create a novel strategy to improve the way clinical trials are carried out in the field of rare diseases and precision medicine. The businesses are looking into ways to facilitate the recruitment of a broad patient base and enhance their overall clinical trial approach.           
  • Oxford Biomedica bought ABL Europe outright from Institut Mérieux in December 2023. Through this agreement, Oxford Biomedica will be able to provide multiviral vector CDMO capabilities to its six manufacturing locations located in the EU, US, and UK. Additionally, this will enhance Oxford Biomedica's capacity for handling and improve its ability to build analytical tools and early-stage production procedures to better meet customer needs. The establishment of new facilities in France will boost process research and manufacturing capability within the EU.